# The role of tryptophan-AhR signaling in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD): implications for therapeutic strategies

**Authors:** Yinan Zhao, Shuhao Cheng, Jiu Liang, Guoying Yu

PMC · DOI: 10.3389/fimmu.2026.1806118 · Frontiers in Immunology · 2026-03-18

## TL;DR

This paper explores how the tryptophan-AhR signaling pathway contributes to liver disease and its potential as a target for new treatments.

## Contribution

The paper highlights the novel role of tryptophan-AhR signaling in MASLD pathogenesis and its therapeutic potential.

## Key findings

- Dysregulated tryptophan metabolism and AhR signaling contribute to MASLD progression.
- AhR activation modulates inflammation, oxidative stress, and lipid metabolism in the liver.
- Modulating the tryptophan-AhR axis could offer new therapeutic strategies for MASLD.

## Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global health concern, closely associated with metabolic syndrome and characterized by hepatic fat accumulation, inflammation, and fibrosis. While the pathogenesis of MASLD is multifactorial, recent research has highlighted the role of the tryptophan-aryl hydrocarbon receptor (AhR) signaling pathway in influencing both immune and metabolic functions in the liver. Tryptophan, an essential amino acid, is metabolized into various bioactive metabolites, such as kynurenine, that activate AhR. This activation modulates cellular processes including inflammation, oxidative stress, and lipid metabolism. Emerging evidence suggests that dysregulated tryptophan metabolism and AhR signaling contribute to the progression of MASLD, particularly through immune modulation and alterations in metabolic pathways. This perspective aims to provide an overview of the current understanding of tryptophan-AhR signaling in MASLD, discussing its potential as a therapeutic target and the challenges associated with targeting this pathway. Future research directions are proposed to explore how modulation of the tryptophan-AhR axis could offer novel therapeutic strategies for MASLD, providing new insights into its treatment and management.

## Linked entities

- **Proteins:** AHR (aryl hydrocarbon receptor)
- **Chemicals:** tryptophan (PubChem CID 1148), kynurenine (PubChem CID 846)
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** AHR (aryl hydrocarbon receptor) [NCBI Gene 196] {aka FVH3, RP85, bHLHe76}
- **Diseases:** fibrosis (MESH:D005355), metabolic syndrome (MESH:D024821), MASLD (MESH:D008107), inflammation (MESH:D007249)
- **Chemicals:** acid (MESH:D000143), Tryptophan (MESH:D014364), lipid (MESH:D008055), kynurenine (MESH:D007737)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13038574/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13038574/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC13038574/full.md

---
Source: https://tomesphere.com/paper/PMC13038574